UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 28, 2019

IDEXX LABORATORIES, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

000-19271
(Commission File Number)

01-0393723
(IRS Employer Identification No.)

One IDEXX Drive, Westbrook, Maine
(Address of principal executive offices)

207.556.0300
(Registrant's telephone number, including area code)

207
(ZIP Code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<table>
<thead>
<tr>
<th>Title of each class</th>
<th>Trading Symbol(s)</th>
<th>Name of each exchange on which registered</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock, $0.10 par value per share</td>
<td>IDXX</td>
<td>NASDAQ Global Select Market</td>
</tr>
</tbody>
</table>

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On July 1, 2019, IDEXX Laboratories, Inc. (the “Company”) announced that Jonathan W. Ayers, the Company’s Chairman of the Board, President and Chief Executive Officer, is taking a medical leave of absence following a serious bicycling accident that occurred on June 27, 2019. In connection with Mr. Ayers’s leave of absence, the Company’s Board of Directors appointed Jay Mazelsky, 58, as the Company’s Interim President and Chief Executive Officer, effective June 28, 2019.

A copy of the Company’s press release announcing these matters and containing certain biographical information concerning Mr. Mazelsky is attached hereto as Exhibit 99.1 and incorporated herein by this reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<table>
<thead>
<tr>
<th>Exhibit No.</th>
<th>Description of Exhibit</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.1</td>
<td>Press Release entitled “IDEXX Laboratories Chairman, President and Chief Executive Officer, Jonathan Ayers, Taking Medical Leave of Absence,” issued by the Company on July 1, 2019.</td>
</tr>
</tbody>
</table>
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IDEXX LABORATORIES, INC.

Date: July 1, 2019

By: /s/ Sharon E. Underberg

Sharon E. Underberg
Corporate Vice President, General Counsel and Secretary
IDEXX Laboratories Chairman, President and Chief Executive Officer, Jonathan Ayers, Taking Medical Leave of Absence

Jay Mazelsky, Executive Vice President, Companion Animal Group, Appointed Interim President and Chief Executive Officer

WESTBROOK, Maine, July 1, 2019 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announced that Chairman, President and Chief Executive Officer, Jonathan Ayers, is on a medical leave of absence following a serious bicycling accident that occurred on June 27, 2019.

Effective June 28, 2019, the IDEXX Board of Directors has appointed Jay Mazelsky as Interim President and Chief Executive Officer. Mr. Mazelsky will assume Mr. Ayers's day-to-day management responsibilities and work closely with Brian McKeon, Chief Financial Officer, who will continue to be responsible for the Company's finances and investor relations. Larry Kingsley, independent Lead Director of the IDEXX Board, will provide additional support to Jay, Brian and the management team.

"First and foremost, we support Jon and his family and wish him a speedy and full recovery," said Mr. Kingsley, Lead Director of the IDEXX Board. "Jon is a passionate, dedicated and well-respected leader of IDEXX. Jon has expressed his confidence in Jay, Brian and IDEXX's talented leadership team to continue to advance the Company's Purpose to enhance the health and well-being of pets, people, and livestock. IDEXX is well-positioned for the future, and the Board is confident that IDEXX's extremely capable executives and employees will continue successfully executing the Company's strategy and creating value for shareholders."

About Jay Mazelsky

Prior to his appointment as Interim President and Chief Executive Officer of IDEXX, Mr. Mazelsky, 58, has been an Executive Vice President since joining IDEXX in August 2012. In addition to his day-to-day management responsibilities as Interim President and Chief Executive Officer, he oversees the Company's North American Companion Animal Group Commercial Organization and key elements of the innovation portfolio, including IDEXX's global in-house diagnostics and Veterinary Software and Service's businesses. From 2007 to 2012, Mr. Mazelsky was a Senior Vice President and General Manager of a number of businesses at Philips Healthcare.

About Brian McKeon

Mr. McKeon, 57, has been Executive Vice President, Chief Financial Officer, and Treasurer since January 2014. He leads IDEXX's finance, corporate development and strategy and worldwide operations functions. Mr. McKeon served as a Director of IDEXX from July 2003 through December 2013, including serving as Chair of the Audit Committee and as a member of the Compensation Committee.

About IDEXX Laboratories

IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX employs more than 8,000 people and offers products to customers in over 175 countries. For more information about IDEXX and additional background on Mr. Mazelsky and Mr. McKeon, visit: www.idexx.com.

Note Regarding Forward-Looking Statements

This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," "project," and similar words and expressions. These forward-looking statements are intended to provide our current expectation or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to United States securities laws contain discussions of these risks and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review IDEXX's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at www.sec.gov and via IDEXX's website at www.idexx.com).

Contact:

Investor Relations:
John Ravis
1-207-556-8155
john-ravis@idexx.com